publication date: Feb. 19, 2021

Clinical Roundup

NCCN guidelines analyze evidence for nephroblastoma

The National Comprehensive Cancer Network published its first-ever treatment guidelines for children with a solid tumor cancer type in the United States.

The NCCN Clinical Practice Guidelines in Oncology for Wilms Tumor (Nephroblastoma) contain evidence-based expert consensus recommendations for how to maximize benefits and minimize side effects for managing a rare type of kidney cancer that typically occurs in children age eight years or younger.

These guidelines contain crucial information, particularly for care providers who treat a full spectrum of pediatric tumors, hematologic malignancies, and other blood disorders (such as sickle cell), due to the relative infrequency of all of these conditions. The guidelines also include important diagnostic information for primary care pediatricians to help ensure this cancer is caught early enough to benefit from high curability rates, and managed in a way that reduces side effects.

“The NCCN Guidelines for Wilms Tumor provide compiled, annotated, and vetted recommendations for diagnosis, treatment, and follow up—in keeping with NCCN’s goals for streamlining and improving care so that patients can live better lives,” said Elizabeth Mullen, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and  ember of the NCCN Guidelines Panel for Wilms Tumor. “People say Wilms is a ‘good cancer’ because it has a 90 percent cure rate but that still means too many children don’t survive. I won’t feel okay until we get that cure rate to 100%—with optimization of long-term wellness, fertility, and psycho-social wellbeing.”

The treatment of Wilms tumor is guided by the results of a series of sequential clinical trials that started back in the 1960s, said Frank M. Balis, professor of pediatrics, Louis and … Continue reading NCCN guidelines analyze evidence for nephroblastoma

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2021 The Cancer Letter Inc.